张宏耕教授表示："抑郁和睡眠障碍互为风险因素，因此指南建议两者同时治疗，而且抑郁症状伴失眠 时，睡眠改善有益于疾病症状的改善，治疗早期有益于提高患者依从性。" 张宏耕教授强调，中医药在识别和治疗抑郁症与失眠方面具有独特优势，通过辨证论治，可精准识别不 同证型，采用个性化的治疗方案，从而提高治疗效果。从中医角度来讲，抑郁症患者中实证患者占比相 张宏耕教授在会上作学术报告 6月21日，慢病(络病)防治中国行暨2025年络病学术会议以线上线下相结合的方式同时在长沙、武汉、 广州举行，会议以长沙为主会场，三市联动，吸引了来自精神卫生领域的数百名专家学者参会，就络病 理论指导失眠、抑郁等疾病治疗取得的科研成果进行了深入交流和探讨。在长沙主会场，湖南省第二人 民医院张宏耕教授作题为《中西医对"郁证与不寐"的认识》的学术报告，介绍了抑郁症和失眠的关系， 强调了创新中药解郁除烦胶囊治疗抑郁、益肾养心安神片治疗失眠的良好临床效果。 张宏耕教授介绍，抑郁症是以各种原因引起、以显著且持久的心境低落为主要特征的心境障碍，病程持 续至少2周，属中医的"郁证""百合病""脏燥"等范畴；失眠症则是以频繁而持续(2～3周)的入睡困难和 (或 ...

Core Viewpoint - Yiling Pharmaceutical reported a net loss for 2024 due to revenue reduction from expiring respiratory products and increased inventory impairment, but maintains high R&D investment levels, with over 900 million yuan allocated, representing 13.94% of revenue, which is leading in the industry [1][5]. R&D Investment - Yiling Pharmaceutical has a strong R&D capability based on its unique theory of network disease, which has led to a nearly 25-fold increase in R&D investment since 2008 [2]. - The company continues to maintain high R&D investment levels, with 900 million yuan in 2024, ranking among the top in the industry [5]. Product Development and Pipeline - The company has 17 patented new drugs, with 11 included in the national medical insurance directory and 5 in the national essential drug list [5]. - Yiling Pharmaceutical has ongoing registration applications for two innovative traditional Chinese medicine products and three chemical drug products, enhancing its product pipeline [6]. Market Performance - Yiling Pharmaceutical's respiratory and cardiovascular products lead their respective markets, with Lianhua Qingwen capturing 24.36% of the cold medicine market in public healthcare [7]. - The company’s core cardiovascular products hold a combined market share of 17.69% in the public healthcare sector [7]. New Growth Areas - The company is expanding into the health and wellness sector, with products targeting blood lipid regulation, sleep improvement, and blood sugar control [8]. - Yiling Pharmaceutical's OTC product Baizi Bujin Capsule is highlighted as a potential new pillar product, supported by extensive evidence from clinical studies [8].